202 related articles for article (PubMed ID: 15486535)
1. Drotrecogin alfa (activated) for the treatment of severe sepsis and septic shock.
Rice TW; Bernard GR
Am J Med Sci; 2004 Oct; 328(4):205-14. PubMed ID: 15486535
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of recombinant human activated protein C for severe sepsis.
Bernard GR; Vincent JL; Laterre PF; LaRosa SP; Dhainaut JF; Lopez-Rodriguez A; Steingrub JS; Garber GE; Helterbrand JD; Ely EW; Fisher CJ;
N Engl J Med; 2001 Mar; 344(10):699-709. PubMed ID: 11236773
[TBL] [Abstract][Full Text] [Related]
3. Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis.
Bernard GR
Crit Care Med; 2003 Jan; 31(1 Suppl):S85-93. PubMed ID: 12544981
[TBL] [Abstract][Full Text] [Related]
4. Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis.
McCoy C; Matthews SJ
Clin Ther; 2003 Feb; 25(2):396-421. PubMed ID: 12749504
[TBL] [Abstract][Full Text] [Related]
5. Drotrecogin alfa (activated) in an infant with gram-negative septic shock.
Sajan I; Da-Silva SS; Dellinger RP
J Intensive Care Med; 2004; 19(1):51-5. PubMed ID: 15035755
[TBL] [Abstract][Full Text] [Related]
6. Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis.
De Backer D
Drug Saf; 2007; 30(11):995-1010. PubMed ID: 17973539
[TBL] [Abstract][Full Text] [Related]
7. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.
Vincent JL; Angus DC; Artigas A; Kalil A; Basson BR; Jamal HH; Johnson G; Bernard GR;
Crit Care Med; 2003 Mar; 31(3):834-40. PubMed ID: 12626993
[TBL] [Abstract][Full Text] [Related]
8. New additions to the intensive care armamentarium.
Rice TW; Bernard GR
Drugs Today (Barc); 2004 Feb; 40(2):157-70. PubMed ID: 15045037
[TBL] [Abstract][Full Text] [Related]
9. Drotrecogin alfa (activated) treatment in a neonate with sepsis and multi organ failure.
Albuali WH; Singh RN; Fraser DD; Scott LA; Kornecki A
Saudi Med J; 2005 Aug; 26(8):1289-92. PubMed ID: 16127532
[TBL] [Abstract][Full Text] [Related]
10. Drotrecogin alfa (recombinant human activated protein C) in severe acute pancreatitis.
Jamdar S; Siriwardena AK
Crit Care; 2005 Aug; 9(4):321-2. PubMed ID: 16137370
[TBL] [Abstract][Full Text] [Related]
11. Drotrecogin alfa (activated) in the treatment of severe sepsis.
Vincent JL
Curr Drug Saf; 2007 Sep; 2(3):227-31. PubMed ID: 18690972
[TBL] [Abstract][Full Text] [Related]
12. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.
Ely EW; Laterre PF; Angus DC; Helterbrand JD; Levy H; Dhainaut JF; Vincent JL; Macias WL; Bernard GR;
Crit Care Med; 2003 Jan; 31(1):12-9. PubMed ID: 12544987
[TBL] [Abstract][Full Text] [Related]
13. [Report of the 6th German Interdisciplinary Congress of Intensive and Emergency Medicine. Initial experiences with the new anti-infective drug drotrecogin alfa (activated) in septic shock].
Krankenpfl J; 2003; 41(1-3):27-9. PubMed ID: 12718261
[No Abstract] [Full Text] [Related]
14. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment.
Vincent JL; Bernard GR; Beale R; Doig C; Putensen C; Dhainaut JF; Artigas A; Fumagalli R; Macias W; Wright T; Wong K; Sundin DP; Turlo MA; Janes J
Crit Care Med; 2005 Oct; 33(10):2266-77. PubMed ID: 16215381
[TBL] [Abstract][Full Text] [Related]
15. Biomarker response to drotrecogin alfa (activated) in children with severe sepsis: results from the RESOLVE clinical trial*.
Dalton HJ; Carcillo JA; Woodward DB; Short MA; Williams MD
Pediatr Crit Care Med; 2012 Nov; 13(6):639-45. PubMed ID: 22791090
[TBL] [Abstract][Full Text] [Related]
16. Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated).
Levy H; Laterre PF; Bates B; Qualy RL
Crit Care; 2005 Oct; 9(5):R502-7. PubMed ID: 16277711
[TBL] [Abstract][Full Text] [Related]
17. An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures.
Betancourt M; McKinnon PS; Massanari RM; Kanji S; Bach D; Devlin JW
Pharmacoeconomics; 2003; 21(18):1331-40. PubMed ID: 14750900
[TBL] [Abstract][Full Text] [Related]
18. Drotrecogin alfa (activated) in sepsis: initial experience with patient selection, cost, and clinical outcomes.
Higgins TL; Steingrub JS; Tereso GJ; Tidswell MA; McGee WT
J Intensive Care Med; 2005; 20(6):339-45. PubMed ID: 16280407
[TBL] [Abstract][Full Text] [Related]
19. Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.
Barton P; Kalil AC; Nadel S; Goldstein B; Okhuysen-Cawley R; Brilli RJ; Takano JS; Martin LD; Quint P; Yeh TS; Dalton HJ; Gessouron MR; Brown KE; Betts H; Levin M; Macias WL; Small DS; Wyss VL; Bates BM; Utterback BG; Giroir BP
Pediatrics; 2004 Jan; 113(1 Pt 1):7-17. PubMed ID: 14702440
[TBL] [Abstract][Full Text] [Related]
20. Risk-benefit analysis for drotrecogin alfa (activated).
Schein RM; Kinasewitz GT
Am J Surg; 2002 Dec; 184(6A Suppl):S25-38. PubMed ID: 12521615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
